{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:15:21Z","timestamp":1791281721042,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.nano.2011.08.014","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T07:13:32Z","timestamp":1315638812000},"page":"731-739","source":"Crossref","is-referenced-by-count":65,"title":["Enhanced delivery of \u03b1-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders"],"prefix":"10.1016","volume":"8","author":[{"given":"Janet","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tridib","family":"Bhowmick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2011.08.014_bb0005","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.nano.2011.08.014_bb0010","first-page":"3389","article-title":"Glycogen storage disease type II: acid \u03b1-glucosidase (acid maltase) deficiency","volume":"Vol. 3","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.nano.2011.08.014_bb0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.nmd.2008.04.010","article-title":"Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle","volume":"18","author":"Malicdan","year":"2008","journal-title":"Neuromuscul Disord"},{"issue":"Suppl 1","key":"10.1016\/j.nano.2011.08.014_bb0020","first-page":"S42","article-title":"Autophagy in skeletal muscle: implications for Pompe disease","volume":"47","author":"Shea","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.nano.2011.08.014_bb0025","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MOP.0b013e3282f161f2","article-title":"Enzyme reconstitution\/replacement therapy for lysosomal storage diseases","volume":"19","author":"Burrow","year":"2007","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.nano.2011.08.014_bb0030","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1006\/bbrc.2000.3555","article-title":"Correction of glycogen storage disease type II by enzyme replacement with a recombinant human acid maltase produced by over-expression in a CHO-DHFR(neg) cell line","volume":"276","author":"Martiniuk","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nano.2011.08.014_bb0035","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1468-1331.2008.02377.x","article-title":"Glycogen storage disease type II (Pompe disease)\u2014influence of enzyme replacement therapy in adults","volume":"16","author":"Merk","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.nano.2011.08.014_bb0040","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nurt.2008.08.009","article-title":"Therapeutic approaches in glycogen storage disease type II\/Pompe disease","volume":"5","author":"Schoser","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nano.2011.08.014_bb0045","first-page":"77","article-title":"The uptake of enzymes into lysosomes: an overview","volume":"16","author":"Neufeld","year":"1980","journal-title":"Birth Defects Orig Article Ser"},{"key":"10.1016\/j.nano.2011.08.014_bb0050","first-page":"547","article-title":"Receptor-mediated uptake of lysosomal enzymes","volume":"23","author":"Sly","year":"1978","journal-title":"Prog Clin Biol Res"},{"key":"10.1016\/j.nano.2011.08.014_bb0055","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11910-007-0024-4","article-title":"Acid alpha-glucosidase deficiency (Pompe disease)","volume":"7","author":"Fukuda","year":"2007","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nano.2011.08.014_bb0060","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"Pathogenetics"},{"key":"10.1016\/j.nano.2011.08.014_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nano.2011.08.014_bb0070","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/ana.20807","article-title":"Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease","volume":"59","author":"Fukuda","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nano.2011.08.014_bb0075","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nano.2011.08.014_bb0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.nano.2011.08.014_bb0085","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jgm.1511","article-title":"Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease","volume":"12","author":"Sun","year":"2010","journal-title":"J Gene Med"},{"key":"10.1016\/j.nano.2011.08.014_bb0090","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2249.2008.03602.x","article-title":"Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model","volume":"152","author":"Joseph","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nano.2011.08.014_bb0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nano.2011.08.014_bb0100","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.nano.2011.08.014_bb0105","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/jpet.107.133298","article-title":"Delivery of acid sphingomyelinase in normal and Niemann-Pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers","volume":"325","author":"Garnacho","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nano.2011.08.014_bb0110","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jconrel.2010.10.031","article-title":"Enhanced endothelial delivery and biochemical effects of alpha-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease","volume":"149","author":"Hsu","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2011.08.014_bb0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/wnan.73","article-title":"New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders","volume":"2","author":"Muro","year":"2010","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.nano.2011.08.014_bb0120","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/mt.2008.127","article-title":"Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers","volume":"16","author":"Muro","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.nano.2011.08.014_bb0125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymthe.2005.07.687","article-title":"Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis","volume":"13","author":"Muro","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.nano.2011.08.014_bb0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0092-8674(87)90104-8","article-title":"Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1)","volume":"51","author":"Marlin","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.nano.2011.08.014_bb0135","series-title":"Endothelial biomedicine","first-page":"1058","article-title":"Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1","author":"Muro","year":"2007"},{"key":"10.1016\/j.nano.2011.08.014_bb0140","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1242\/jcs.00367","article-title":"A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1","volume":"116","author":"Muro","year":"2003","journal-title":"J Cell Sci"},{"key":"10.1016\/j.nano.2011.08.014_bb0145","doi-asserted-by":"crossref","first-page":"C1339","DOI":"10.1152\/ajpcell.00099.2003","article-title":"Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress","volume":"285","author":"Muro","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.nano.2011.08.014_bb0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-0854.2000.011101.x","article-title":"Membrane traffic in sphingolipid storage diseases","volume":"1","author":"Pagano","year":"2000","journal-title":"Traffic"},{"key":"10.1016\/j.nano.2011.08.014_bb0155","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2174\/138920111795542606","article-title":"Pompe disease: from new views on pathophysiology to innovative therapeutic strategies","volume":"12","author":"Parenti","year":"2011","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.nano.2011.08.014_bb0160","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/ki.1990.221","article-title":"Differing regulation and function of ICAM-1 and class II antigens on renal tubular cells","volume":"38","author":"Jevnikar","year":"1990","journal-title":"Kidney Int"},{"key":"10.1016\/j.nano.2011.08.014_bb0165","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1124\/jpet.105.098970","article-title":"Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1","volume":"317","author":"Muro","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nano.2011.08.014_bb0170","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jconrel.2007.09.013","article-title":"Nano\/micro technologies for delivering macromolecular therapeutics using poly(d,l-lactide-co-glycolide) and its derivatives","volume":"125","author":"Mundargi","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2011.08.014_bb0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","article-title":"Biodegradable nanoparticles for drug and gene delivery to cells and tissue","volume":"55","author":"Panyam","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2011.08.014_bb0180","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/BF01805584","article-title":"alpha-glucosidase in Pompe's disease","volume":"1","author":"Broadhead","year":"1978","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nano.2011.08.014_bb0185","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10545-009-9027-4","article-title":"PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease","volume":"33","author":"Hagemans","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.nano.2011.08.014_bb0190","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0009-8981(98)00183-1","article-title":"Elevated lysosomal pH in mucolipidosis type IV cells","volume":"280","author":"Bach","year":"1999","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.nano.2011.08.014_bb0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jconrel.2010.10.025","article-title":"Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers","volume":"150","author":"Calderon","year":"2011","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2011.08.014_bb0200","first-page":"3589","article-title":"Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies","volume":"Vol. 3","author":"Schuchman","year":"2001"},{"key":"10.1016\/j.nano.2011.08.014_bb0205","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","volume":"Vol. 3","author":"Desnick","year":"2001"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411003510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411003510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:29:41Z","timestamp":1543537781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963411003510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S1549963411003510"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2011.08.014","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}